Exploring ways to suppress manifestation of type 2 diabetes mellitus and coexist with fat

Exploring ways to suppress manifestation of type 2 diabetes mellitus and coexist with fat - Exploring ways to suppress manifestation of type 2 diabetes mellitus and coexist with fat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026921

Enrollment

Registered

2017-04-10

Start date

2017-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Clinical Examination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are included in this study: 1. Female or male patients with fatty liver aged 20 to 70 years old, and possibly with fat accumulation in their muscle 2. Fatty liver with deviation enzyme, ALT over 30 IU/L at blood sampling 3. Patient who can go through the process of hepatic biopsy 4. Patients' HbA1c has to be below 10% if they are using glinide, alpha-glucosidase inhibitor, or a small amount of SU (Amaryl 2 mg or less) 5. Patients who can give their written consent to participant in this study

Exclusion criteria

Exclusion criteria: Patients who fall into any of the following criteria are excluded from participating in the study: 1. Patients with type 1 diabetes or secondary diabetes 2. Patients with moderate to severe renal function disease or at the terminal stage of renal failure (eGFR< 45mL/min/1.73m2) 3. Patients who had stroke or cerebral infarction within 12 weeks before giving their consent 4. Patients with myocardial infarction or angina pectoris in the past, or currently with atrial fibrillation 5. Patients with other conditions that the investigator/researcher thinks inappropriate for the study

Design outcomes

Primary

Measure	Time frame
1. Quantitative measure of intracellular lipid accumulation in each insulin target organ 2. Quantitative value of insulin sensitivity in each insulin target organ 3. Quantitative amount of whole-body fat and muscle mass, intraperitoneal adipose and subcutaneous fat 4. Information regarding patient's life style 5. Urine and blood test results 6. Gene expression profiling and hepatic histopathological evaluation 7. Measurement results of respiratory quotient 8. Other exploratory items	—

Measure

Time frame

1. Quantitative measure of intracellular lipid accumulation in each insulin target organ 2. Quantitative value of insulin sensitivity in each insulin target organ 3. Quantitative amount of whole-body fat and muscle mass, intraperitoneal adipose and subcutaneous fat 4. Information regarding patient's life style 5. Urine and blood test results 6. Gene expression profiling and hepatic histopathological evaluation 7. Measurement results of respiratory quotient 8. Other exploratory items

—

Countries

Japan

Contacts

Public ContactNaoki Kumashiro

Toho University Omori Medical Center Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

naoki.kumashiro@med.toho-u.ac.jp03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026